$360,000 of EDWARDS LIFESCIENCES LLC lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Ensuring Patient Access to Critical Breakthrough Products (S.1717) Transitional Coverage for Emerging Technologies (TCET) Guidance Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization for 2022/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (s.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development Corporate Tax Reform Proposals Tariffs"
You can find more data on corporate lobbying on Quiver Quantitative.
EW Congressional Stock Trading
Members of Congress have traded $EW stock 5 times in the past 6 months. Of those trades, 3 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $EW stock by members of Congress over the last 6 months:
- REPRESENTATIVE JEFFERSON SHREVE has traded it 2 times. They made 1 purchase worth up to $50,000 on 04/07 and 1 sale worth up to $100,000 on 05/12.
- REPRESENTATIVE BRUCE WESTERMAN has traded it 2 times. They made 1 purchase worth up to $15,000 on 03/03 and 1 sale worth up to $15,000 on 04/21.
- REPRESENTATIVE ROBERT BRESNAHAN purchased up to $15,000 on 04/08.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
EW Insider Trading Activity
EW insiders have traded $EW stock on the open market 23 times in the past 6 months. Of those trades, 0 have been purchases and 23 have been sales.
Here’s a breakdown of recent trading of $EW stock by insiders over the last 6 months:
- SCOTT B. ULLEM (CVP, Chief Financial Officer) has made 0 purchases and 5 sales selling 45,000 shares for an estimated $3,282,900.
- BERNARD J ZOVIGHIAN (CEO) has made 0 purchases and 4 sales selling 29,210 shares for an estimated $2,194,261.
- DONALD E JR BOBO (CVP,Strategy/Corp Development) has made 0 purchases and 5 sales selling 28,070 shares for an estimated $2,000,094.
- LARRY L WOOD (Global President TAVR & Surg) sold 8,950 shares for an estimated $673,268
- STEVEN R LORANGER sold 5,739 shares for an estimated $438,575
- HEISZ LESLIE STONE sold 5,739 shares for an estimated $435,370
- DAVEEN CHOPRA (CVP, TMTT) sold 1,500 shares for an estimated $112,612
- DANIEL J. LIPPIS (CVP, JAPAC) has made 0 purchases and 4 sales selling 1,530 shares for an estimated $111,704.
- WAYNE MARKOWITZ (GM & SVP, Surgical) sold 268 shares for an estimated $20,120
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
EW Hedge Fund Activity
We have seen 482 institutional investors add shares of EW stock to their portfolio, and 610 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 7,110,139 shares (+47.9%) to their portfolio in Q1 2025, for an estimated $515,342,874
- DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN added 4,247,627 shares (+5595.5%) to their portfolio in Q1 2025, for an estimated $307,868,004
- WELLINGTON MANAGEMENT GROUP LLP removed 4,076,089 shares (-12.3%) from their portfolio in Q1 2025, for an estimated $295,434,930
- CITADEL ADVISORS LLC added 3,963,609 shares (+42.1%) to their portfolio in Q1 2025, for an estimated $287,282,380
- MILLENNIUM MANAGEMENT LLC added 3,216,598 shares (+1409.8%) to their portfolio in Q1 2025, for an estimated $233,139,023
- MARSHALL WACE, LLP removed 2,782,748 shares (-47.9%) from their portfolio in Q1 2025, for an estimated $201,693,575
- JENNISON ASSOCIATES LLC added 2,576,383 shares (+34.3%) to their portfolio in Q1 2025, for an estimated $186,736,239
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
EW Analyst Ratings
Wall Street analysts have issued reports on $EW in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 07/16/2025
- Citigroup issued a "Buy" rating on 05/22/2025
- Piper Sandler issued a "Overweight" rating on 05/13/2025
- Barclays issued a "Overweight" rating on 02/13/2025
- RBC Capital issued a "Outperform" rating on 02/12/2025
- Stifel issued a "Buy" rating on 01/30/2025
To track analyst ratings and price targets for EW, check out Quiver Quantitative's $EW forecast page.
EW Price Targets
Multiple analysts have issued price targets for $EW recently. We have seen 11 analysts offer price targets for $EW in the last 6 months, with a median target of $83.0.
Here are some recent targets:
- Anthony Petrone from Mizuho set a target price of $87.0 on 07/16/2025
- Patrick Wood from Morgan Stanley set a target price of $81.0 on 07/15/2025
- Vijay Kumar from Evercore ISI Group set a target price of $77.0 on 07/08/2025
- Joanne Wuensch from Citigroup set a target price of $95.0 on 05/22/2025
- Adam Maeder from Piper Sandler set a target price of $83.0 on 05/13/2025
- William Plovanic from Canaccord Genuity set a target price of $75.0 on 04/25/2025
- David Rescott from Baird set a target price of $75.0 on 04/24/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
